EMERYVILLE, Calif., Sept. 28 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) , a biotechnology company engaged in the business of acquiring and developing central nervous system (CNS) related drug candidates, today announced that it has promoted Karl G. Trass to the newly created position of Vice President of Regulatory Affairs and Quality Assurance.
Paul Freiman, president and CEO of NTI, said, “Karl’s years of experience in regulatory affairs and new product development have strengthened our company measurably. He continues to perform at the highest level and the Board wanted to recognize his contribution.”
Trass, age 45, joined NTI in January 2005 as the Company’s Director of Regulatory Affairs. Since then, he has been responsible for interaction with regulatory agencies in the US and overseas. He came to NTI with twelve years of regulatory affairs experience, including regulatory strategy during development and post-marketing for oncology, anti-viral, anti-inflammatory, cardiovascular, and endocrine drug products: small molecules, biologics, gene transfer agents, and diagnostics. Specific therapeutic areas of his expertise include: diabetic neuropathy, HIV, breast cancer, diabetes, obesity, CMV, psoriasis, AMI, pain, and transplant. He also has extensive regulatory interaction with the FDA in the US, as well as regulators in Canada, the UK, Australia and Europe.
Before joining NTI, Trass was Director of Regulatory Affairs with Sangamo BioSciences of Richmond, CA. He held the same position at Gilead Sciences in Foster City, CA, and was Associate Director of Regulatory Affairs for Tularik in South San Francisco. Earlier, he was Senior Manager for Regulatory Affairs at GenenTech, also in South San Francisco, Senior Associate for Regulatory Affairs with Syntex of Palo Alto, and Regulatory Associate for Hybritech, in San Diego. Trass holds a bachelor’s degree from Indiana University where he studied chemistry.
About Neurobiological Technologies, Inc.
NTI is an emerging drug development company focused on the clinical evaluation and regulatory approval of neuroscience drugs. The company’s strategy is to in-license and develop early- and later-stage drug candidates that target major medical needs and which can be rapidly commercialized. NTI’s experienced management team oversees the human clinical trials necessary to establish preliminary evidence of efficacy and seeks partnerships with pharmaceutical and biotechnology companies to complete development and marketing of its product candidates.
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including: risks associated with the costs of clinical development efforts and the ability of our expanded management team to work together, and other risks detailed from time to time in our Securities and Exchange Commission filings. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. We disclaim, however, any intent or obligation to update these forward-looking statements.
Neurobiological Technologies, Inc.
CONTACT: Paul E. Freiman, President & CEO, of NeurobiologicalTechnologies, Inc., +1-510-595-6000; or Cheryl Schneider, VP - InvestorRelations, or Jeff Myhre, VP - Editorial, both of Porter, Le Vay & Rose,Inc., +1-212-564-4700, for Neurobiological Technologies, Inc.
Web site: http://www.ntii.com//
